Norris Medicines Limited has informed the stock exchanges about the resignation of Ms. Sathya Venkatachalam from her position as Independent Director, effective December 12, 2025. The company made this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Resignation Details

Ms. Sathya Venkatachalam (DIN: 06970735) submitted her resignation letter dated December 10, 2025, with the resignation becoming effective from December 12, 2025. The director cited personal reasons for her decision to step down from the board.

Committee Positions

Following her resignation from the board, Ms. Venkatachalam has also stepped down from all company committees where she held membership. Notably, she served as the Chairperson of the Audit Committee at Norris Medicines Limited.

Regulatory Compliance

The company has fulfilled its disclosure obligations by providing the required information under Regulation 30 read with Schedule III-Part A(7B) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also complies with relevant SEBI circulars including CIR/CFD/CMD/4/2015 dated September 9, 2015, and SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023.

Director's Confirmation

Ms. Sathya Venkatachalam has confirmed that there are no other material reasons for her resignation beyond the personal reasons mentioned in her resignation letter. This confirmation was provided as part of the regulatory disclosure requirements for director resignations.

The resignation letter and related documentation have been submitted to BSE Limited, where Norris Medicines Limited is listed with scrip code 524414 and ISIN INE744C01029.

Norris Medicines Limited has successfully completed a comprehensive regulatory audit conducted by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), marking a significant milestone in the company's international operations.

Audit Completion Details

The regulatory inspection was completed on December 9, 2025, following a thorough review of the company's operations. The audit results demonstrate Norris Medicines' commitment to maintaining high pharmaceutical standards across its manufacturing processes.

Scope of Inspection

The NAFDAC audit encompassed multiple critical areas of pharmaceutical operations, ensuring comprehensive compliance assessment:

• Quality systems evaluation
• Manufacturing practices review
• Documentation processes assessment
• Compliance parameters verification

The successful completion of this audit with no critical observations reflects the company's robust quality management systems and adherence to international pharmaceutical manufacturing standards.

Regulatory Compliance

Norris Medicines submitted this information to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's proactive disclosure demonstrates its commitment to maintaining transparency with stakeholders regarding significant operational developments.

The successful NAFDAC audit completion strengthens Norris Medicines' position in the Nigerian pharmaceutical market and validates its manufacturing capabilities for international regulatory standards. This achievement supports the company's ongoing efforts to expand its presence in African markets while maintaining stringent quality controls.